

SANOFI-AVENTIS
Form 6-K
June 14, 2007

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of June 2007

Commission File Number: 001-31368

SANOFI-AVENTIS

(Translation of registrant's name into English)

174, avenue de France, 75013 Paris, FRANCE

(Address of principal executive offices)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

Form 20-F Form 40-F

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Edgar Filing: SANOFI-AVENTIS - Form 6-K

Yes No

If Yes marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-

In June 2007, sanofi-aventis issued the press release attached hereto as Exhibit 99.1, which is incorporated herein by reference.

Exhibit List

Exhibit No.	Description
Exhibit 99.1	Press release dated June 13, 2007 FDA Advisory Panel Did Not Recommend Approval for Rimonabant (Zimulti®) for Use in Obese and Overweight Patients with Associated Risk Factors.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Dated: June 14, 2007

SANOFI-AVENTIS

By: /s/ Patricia Kodyra
Name: Patricia Kodyra
Title: Associate Vice President

Financial and Securities Law

Exhibit Index

Exhibit No.	Description
Exhibit 99.1	Press release dated June 13, 2007 FDA Advisory Panel Did Not Recommend Approval for Rimonabant (Zimul®) for Use in Obese and Overweight Patients with Associated Risk Factors.